Surgical Oncology Insight最新文献

{"title":"Bridging the gap: Addressing gastric cancer disparities among Korean Americans through insights from South Korea","authors":"Minji Kwon, Asher J Shin, Ji Hyun Hong, Cameron J. Sabet, Edward Christopher Dee, Peter Ko","doi":"10.1016/j.soi.2025.100177","DOIUrl":"10.1016/j.soi.2025.100177","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100177"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144863382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 1 dose escalation trial of vv-DD-hIL-2-RG-1 (vaccinia virus double deleted) administration by intratumoral injection for metastatic gastrointestinal tumors: The regional immuno-oncology trial - 3 (RIOT-3) protocol","authors":"Brett M. Szeligo ,&nbsp;Shannon Altpeter ,&nbsp;Catherine Lewis ,&nbsp;Albert D. Donnenberg ,&nbsp;Christopher Sherry ,&nbsp;Vera S. Donnenberg ,&nbsp;Paige Mirsky ,&nbsp;Neda Dadgar ,&nbsp;Ali Zaidi ,&nbsp;Nathan Bahary ,&nbsp;Zuqiang Liu ,&nbsp;David L. Bartlett ,&nbsp;Patrick L. Wagner","doi":"10.1016/j.soi.2025.100185","DOIUrl":"10.1016/j.soi.2025.100185","url":null,"abstract":"<div><div>Current treatments for metastatic gastrointestinal malignancies have poor outcomes, necessitating a novel approach to treatment. Oncolytic therapy with vaccinia viruses has previously shown promising results in terms of safety and anti-tumor efficacy. In addition to direct viral cytotoxic effects, oncolytic therapy has the potential to stimulate adaptive immunity against infected tumor cells by altering the tumor microenvironment. The immunostimulatory effects of oncolytic vaccinia vectors have been maximized through the use of recombinant vectors encoding interleukin-2 (IL-2), a potent cytokine that signals T cell activity and proliferation. This report details the use of a novel oncolytic vaccinia vector-- vvDD-hIL-2-RG-1—which encodes a rigid peptide-linked, membrane-bound form of IL-2, designed to maximize the local immunomodulatory activity following intra-tumoral injection.</div><div>RIOT-3 is a phase 1, open-label, single-dose, dose-escalation trial investigating intratumoral injection of vvDD-hIL-2-RG-1. Up to 18 participants with metastatic gastrointestinal cancer who have failed systemic chemotherapy or immunotherapy will be enrolled. The primary study objective is to determine the safety and maximal tolerated and feasible doses for intratumoral injection via a 3 + 3 dose escalation design. Secondary objectives include quantifying viral replication, pharmacokinetics, and immune response to vvDD-hIL-2-RG-1 intratumoral injection, as well as efficacy assessment by RECIST criteria.</div><div>Previous preclinical data in a murine model have demonstrated that IL-2-bound vaccinia oncolytic virus is safe and exerts dose-dependent anti-tumor activity. RIOT-3 will explore the application of this novel oncolytic viral approach in patients with advanced gastrointestinal malignancies who have failed conventional therapies. The trial is registered at ClinicalTrials.gov; NCT07001592 (registered May 6th, 2025).</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parascapular adipofascial free flap for post-parotidectomy reconstruction","authors":"Karolina A. Plonowska-Hirschfeld,&nbsp;Patrik Pipkorn","doi":"10.1016/j.soi.2025.100170","DOIUrl":"10.1016/j.soi.2025.100170","url":null,"abstract":"<div><h3>Background</h3><div>Facial contour defects after parotidectomy are an important aesthetic consideration. While free fat grafts are frequently utilized to restore facial volume, their long-term durability can be variable and volume under-correction due to fat necrosis is a recognized disadvantage, particularly in patients requiring adjuvant radiation.<span><span>¹</span></span> Parascapular vascularized free fat flaps offer an attractive alternative reconstructive approach; in our institutional experience, they can confer more predictable and stable volume of fat transferred with minimal donor site morbidity.<span><span>²</span></span> Herein, we present our approach to adipofascial parascapular free flap harvest for post-parotidectomy facial defects.</div></div><div><h3>Methods</h3><div>This video demonstrates vascularized free parascapular fat flap harvest for reconstruction of a parotidectomy defect. Approaches and techniques are reviewed.</div></div><div><h3>Results</h3><div>We highlight the technical aspects of parascapular free flap reconstruction after resection of a 3.5 cm pleomorphic adenoma in a 32-year-old male. Total parotidectomy with preservation of facial nerve was performed. The cumulative cut-to-close time for ablation and microvascular reconstruction was 210 min.</div></div><div><h3>Conclusion</h3><div>Adipofascial parascapular free flap is an attractive reconstructive option for parotidectomy defects with facial contour distortion.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100170"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144770762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulmonary metastases, colorectal cancer, and survival: Accurate interpretation of the literature","authors":"By Tom Treasure,&nbsp;Fergus Macbeth","doi":"10.1016/j.soi.2025.100187","DOIUrl":"10.1016/j.soi.2025.100187","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100187"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144917864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of ultrarare sarcomas in a high-volume referral center in Latin America","authors":"Dorian Yarih Garcia-Ortega ,&nbsp;José Antonio Ortega-Jiménez ,&nbsp;Itzel Elizabeth Vidal-Sanchez ,&nbsp;Ana Paulina Meléndez-Fernández ,&nbsp;Claudia Haydee Sarai Caro-Sanchez ,&nbsp;Sylvia Veronica Villavicencio-Valencia ,&nbsp;Gabriela Concepción Alamilla-García ,&nbsp;Kuauhyama Luna-Ortiz","doi":"10.1016/j.soi.2025.100156","DOIUrl":"10.1016/j.soi.2025.100156","url":null,"abstract":"<div><h3>Background</h3><div>Ultrarare sarcomas are a diverse group of malignancies with an incidence of less than 1 % of all sarcomas. Due to their rarity, knowledge about their biology and treatment is limited. Most data come from high-income countries, with little representation from Latin America. This study characterizes ultrarare sarcomas’ clinical and pathological features in a Latin American referral center.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted at a high-volume sarcoma center, including patients diagnosed between 2000 and 2020. Histopathological diagnoses were defined by expert pathologists. Demographic, clinical, and treatment data were collected. Statistical analyses included descriptive statistics and Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>We included 148 patients (median age: 42 years, 54.7 % female). The most common histological subtypes were epithelioid sarcoma (19.6 %), myxo-inflammatory fibroblastic sarcoma (12.8 %), and alveolar soft part sarcoma (9.5 %). Most tumors (77.7 %) were high-grade, and 22.3 % had metastases at diagnosis. Surgery was performed in 77.7 % of cases, achieving R0 resection in 51.4 %. Adjuvant radiotherapy was used in 39.9 %, and chemotherapy in 26.4 %. Overall survival was 48.2 months. Metastatic disease, high-grade tumors, and positive margins were associated with worse survival (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>This study highlights the heterogeneity of ultrarare sarcomas and the importance of multidisciplinary management in Latin America. Further research and collaboration are needed to improve outcomes.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 3","pages":"Article 100156"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National disparity in guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis","authors":"Toshiyuki Kitai,&nbsp;Kenya Yamanaka","doi":"10.1016/j.soi.2025.100136","DOIUrl":"10.1016/j.soi.2025.100136","url":null,"abstract":"<div><div>Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) improved survival in appropriately selected patients with peritoneal carcinomatosis. Guideline recommendations are important for its promotion. However, this treatment is not performed widely in Japan. The disparity in practice may be reflected in the national guidelines. Recommendations were compared between 5 sets of guidelines each in Western countries and Japan. 1) The role of CRS was established for colorectal and ovarian cancers whereas that of HIPEC was controversial in Western countries. On the other hand, neither was recommended for colon cancer, and HIPEC was recommended only in research for ovarian cancer in Japan. 2) Potential effects in a limited cases were recognized for gastric cancer in the Western guidelines. 3) Resection for localized metastasis for colon cancer and intraperitoneal chemotherapy for ovarian and gastric cancers were recommended in Japan instead of CRS+HIPEC. 4) CRS+HIPEC is recommended as a first-line treatment for pseudomyxoma peritonei and peritoneal mesothelioma in Western countries but recommended only for pseudomyxoma in Japan. There is a disparity in the guidelines for CRS+HIPEC, which is attributed to not being widely performed in Japan.</div></div><div><h3>Synopsis</h3><div>The disparity in practice may be reflected in the national guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Recommendations were towards to more negative in Japan than in Western countries. This is attributed to not being widely performed in Japan. It is necessary to achieve social consensus on this treatment.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100136"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Yttrium90 transarterial radioembolization as a bridge to surgery in hepatocellular carcinoma","authors":"Amelia WH Wong ,&nbsp;Shirley Cheng ,&nbsp;Anthony Herrera ,&nbsp;Linda Wong","doi":"10.1016/j.soi.2025.100146","DOIUrl":"10.1016/j.soi.2025.100146","url":null,"abstract":"<div><h3>Background</h3><div>Yttrium90 transarterial radioembolization (TARE) is increasingly used for bridging or downstaging to liver transplant(LT) or resection(LR) despite a paucity of data. This study aims to illustrate its efficacy as a bridge to surgery.</div></div><div><h3>Methods</h3><div>HCC patients who received Y90 TARE as their first treatment in Honolulu, HI during 2012–2022 were identified. Wilcoxon, Kruskal-Wallis, and Fischer’s t-tests identified statistical significance.</div></div><div><h3>Results</h3><div>Of 137 patients identified, 29 had advanced disease (stage III/IV) and 68 were LR candidates with inadequate FLR. Y90 TARE downstaged 14 %(n = 5/37) potential LR and one advanced disease to surgery. Of 40 LT candidates, 22 % underwent transplantation: 26 %(n = 7/27) within Milan and 15 %(n = 2/13) within UCSF criteria underwent transplantation. Only 9(22 %) were ineligible due to tumor progression; larger tumor size was the only predictor (&gt;7.5 cm, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>Y90 TARE is an effective bridging therapy but most did not get transplanted for non-tumor reasons (comorbidities, substance abuse). Larger tumor burden and cirrhosis may impact its ability to downstage to resection.</div></div><div><h3>Synopsis</h3><div>This retrospective cohort study of 137 hepatocellular carcinoma patients demonstrates that Y90 TARE is able to successfully bridge 15–26 % of patients to transplantation and 14 % of previously unresectable patients to surgery however larger tumor size and cirrhosis appears to limit its efficacy. Y90 TARE has the potential to be an effective salvage therapy in medically fit individuals however a minority actually proceed to surgery, therefore further studies evaluating multi-modality therapies may improve the prospect of surgical intervention.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100146"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of neighborhood socioeconomic status and ethnic diversity with receipt of adjuvant chemotherapy in stage III colon cancer: A population-based cohort study","authors":"Adom Bondzi-Simpson ,&nbsp;Ramy Behman ,&nbsp;Tiago Ribeiro ,&nbsp;Sheron Perera ,&nbsp;Aisha Lofters ,&nbsp;Rinku Sutradhar ,&nbsp;Vivian Aghanya ,&nbsp;Andrea Covelli ,&nbsp;Rebecca A. Snyder ,&nbsp;Callisia N. Clarke ,&nbsp;Natalie G. Coburn ,&nbsp;Julie Hallet","doi":"10.1016/j.soi.2025.100148","DOIUrl":"10.1016/j.soi.2025.100148","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant chemotherapy reduces cancer recurrence and improves survival in eligible patients. Barriers to care may contribute to inequities in outcomes. We examined the association between neighborhood socioeconomic status (SES) and ethnic diversity with receipt of adjuvant chemotherapy in stage III colon cancer patients.</div></div><div><h3>Methods</h3><div>A population-based retrospective cohort study was conducted on adults undergoing surgery for stage III colon cancer (2007–2020). SES and ethnic diversity, defined by quintiles from census data, were the primary exposures. Outcomes were receipt of medical oncology consultation and adjuvant chemotherapy within 3 months post-surgery. Logistic regression measured the association between each exposure and outcome combination adjusting for confounders. A sub-group analysis was performed on patients who received a medical oncology consultation.</div></div><div><h3>Results</h3><div>Of 14,511 patients, 10,973 (76.5 %) received medical oncology consultation and 8814 (61.4 %) recieved adjuvant chemotherapy. SES and ethnic diversity were not associated with medical oncology consultation after adjusting for age, sex, surgical approach, and comorbidities. However, living in both the lowest SES and highest ethnically diverse neighborhoods were associated with lower odds of adjuvant chemotherapy (OR 0.70; 95 % CI 0.62–0.80 and OR 0.72; 95 % CI 0.64–0.82, respectively). These associations persisted at 6 months post-surgery. Among patients who had a medical oncology consultation, living in both the lowest SES and highest ethnically diverse neighborhoods were associated with lower odds of adjuvant chemotherapy.</div></div><div><h3>Conclusion</h3><div>Living in lower SES and higher ethnically diverse neighborhoods were independently associated with lower odds of adjuvant chemotherapy but not medical oncology consultation, highlighting disparities in outcomes for marginalized patients within a universal healthcare system.</div></div><div><h3>Synopsis</h3><div>We examined the association between neighborhood socioeconomic status (SES) and ethnic diversity with receipt of adjuvant chemotherapy in patients with stage III colon cancer in Ontario, Canada. Patients from the lowest SES or most diverse neighborhoods had a 30 % and 28 % lower odds of receiving chemotherapy, highlighting disparities within a universal healthcare system.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100148"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unseen burden: Exploring caregiver experiences, barriers, and facilitators in foregut cancer care","authors":"Ioannis Liapis ,&nbsp;Jaspinder Sanghera ,&nbsp;Michelle Holland ,&nbsp;Ivan Herbey ,&nbsp;Katie West ,&nbsp;Martin J. Heslin ,&nbsp;Krista Mehari ,&nbsp;Larry Hearld ,&nbsp;Smita Bhatia ,&nbsp;Annabelle L. Fonseca","doi":"10.1016/j.soi.2025.100153","DOIUrl":"10.1016/j.soi.2025.100153","url":null,"abstract":"<div><h3>Introduction</h3><div>Caregivers play a pivotal role in supporting foregut cancer patients, yet their experiences and the challenges they face are overlooked. Understanding caregivers’ experiences and the barriers and facilitators they encounter can inform interventions to improve their well-being and, ultimately, patient outcomes. This study focuses on the lived experiences and the interpersonal factors that shape the caregivers’ journeys.</div></div><div><h3>Methods</h3><div>Semi-structured interviews were conducted with caregivers of patients with foregut cancer receiving treatment at a safety-net hospital in the Deep South. Interviews were recorded, transcribed and qualitatively analyzed using NVivo 14 software. Grounded theory methodology was used to guide analysis. Three co-authors independently coded the data, with intercoder agreement of above 90 %.</div></div><div><h3>Results</h3><div>Of the 15 caregivers interviewed, the majority were female, spouses of the patients, and resided in areas of high socioeconomic deprivation. Three theme categories emerged: caregiver experiences, individual/interpersonal level barriers, and individual/interpersonal level facilitators. Caregivers expressed self-sacrifice and a strong sense of duty, describing caregiving as a priority despite personal hardships. Barriers included psychological distress, financial strain, competing responsibilities, transportation challenges, social isolation, and patient denial. Conversely, facilitators included support from family and friends, religious and spiritual practices, and engagement in support groups.</div></div><div><h3>Conclusion</h3><div>Caregivers of patients with foregut cancer face significant psychological and financial burden, compounded by competing responsibilities and limited social support. Interventions aimed at reducing caregiver burden and enhancing support mechanisms will improve both caregiver well-being and patient outcomes. Future research should focus on strategies that promote these facilitators and address barriers to caregiving.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100153"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144098388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collateral vessel formation affects long-term patency of artificial vessels: Insights from 60 cases of superior vena cava reconstruction combined with thymic tumor resection","authors":"Yongqiang Ao ,&nbsp;Jiahao Jiang ,&nbsp;Shuai Wang ,&nbsp;Jian Gao ,&nbsp;Yuansheng Zheng ,&nbsp;Lijie Tan ,&nbsp;Junzhen Liu ,&nbsp;Jianyong Ding","doi":"10.1016/j.soi.2025.100151","DOIUrl":"10.1016/j.soi.2025.100151","url":null,"abstract":"<div><h3>Background</h3><div>Superior vena cava (SVC) reconstruction combined with total thymic tumor resection is the standard treatment for thymic tumors invading the SVC. Long-term graft patency is a critical to surgical success and patient prognosis. This study evaluates the durability of artificial grafts and identifies factors affecting their long-term patency.</div></div><div><h3>Methods</h3><div>We retrospectively included 60 patients who underwent extended resection of thymic tumors combined with SVC reconstruction between March 2017 and May 2024. Graft patency and collateral vessel formation were assessed using contrast-enhanced CT or magnetic resonance venography every 3–6 months. Clinical characteristics were compared between patients with and without graft occlusion.</div></div><div><h3>Results</h3><div>Among the 60 patients, 43 underwent left brachiocephalic vein-to-right atrial appendage reconstruction, 13 had right brachiocephalic vein-to-right atrial appendage reconstruction, and 4 had bilateral reconstruction. The 1-, 3-, and 5-year survival rates were 91.6 %, 87.0 %, and 79.1 %, respectively. Of 51 patients with graft assessment, the graft patency rate was 88.2 %, with occlusion in six patients occurring 8–20 months postoperatively. Preoperative SVC syndrome and elevated internal jugular venous pressure during SVC clamping were significant predictors of occlusion (p = 0.031, p = 0.0002) and remained independent risk factors (p = 0.046, p = 0.014). Postoperatively observed collateral circulation was significantly associated with graft occlusion (p = 0.0075), particularly newly formed collateral vessels (p = 0.0016). Imaging revealed extensive collateral vessel development, including azygos vein and chest wall veins.</div></div><div><h3>Conclusions</h3><div>Total thymic tumor resection combined with SVC reconstruction provides favorable long-term survival and graft patency. Collateral vessel formation over time may compromise graft patency and eventually lead to graft occlusion.</div></div><div><h3>Synopsis</h3><div>This study evaluates the long-term patency of artificial grafts in SVC reconstruction for thymic tumors, identifying preoperative SVC syndrome, elevated IJVP, and newly developed collateral circulation as key factors predicting or influencing graft occlusion.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100151"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}